HP011-101, HP828-101, and Standard Care for Pressure Ulcers
Primary Purpose
Pressure Ulcers
Status
Withdrawn
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
HP011-101
HP-828-101
Standard Care
Sponsored by
About this trial
This is an interventional treatment trial for Pressure Ulcers
Eligibility Criteria
Inclusion Criteria:
- Subjects must meet all of the following criteria to be eligible for the study:
- Provide informed consent, or informed assent if less than 18 years of age.
- Age 12 years or older, of either sex, and of any race or skin type, provided that their skin color, in the opinion of the Investigator, will not interfere with the study assessments.
- Have a pressure ulcer ≥ 5 cm² and ≤ 100 cm² in area (measured as greatest length x perpendicular width of the area of non-blanching erythema or denuded skin, whichever is greater), and will remain hospitalized for at least three weeks.
- Are capable of maintaining an adequate nutritional status.
- All female subjects must have a negative urinary pregnancy test.
Have, within 12 weeks prior to screening, clinical laboratory test results indicating:
- Serum albumin ≥ 3.0 g/dL (30 g/L)
- Alkaline phosphatase, ALT, AST, BUN and serum creatinine levels < 3x upper limit of the Healthpoint normal range (refer to Section 18.1.2)
- HbA1C ≤ 12%
- Hemoglobin ≥ 10 g/dL
- The most recently obtained values must be evaluated against these criteria. If these values are not available from a blood sample within 12 weeks of screening, blood must be drawn at screening and these laboratory values determined.
- For ulcers that will require surgical debridement prior to enrollment, the wound must be expected to remain a Stage I or Stage II partial thickness wound after debridement.
Exclusion Criteria:
- Subjects meeting any of the following criteria are not eligible to enter the study:
- Have a known hypersensitivity to any of the test articles or their components.
- Have received therapy with another investigational agent within thirty (30) days of screening.
- Are pregnant or nursing.
- Are currently being treated with systemic antibiotics.
- Have received systemic treatment with glucocorticoids for > 10 consecutive days within 1 month prior to the start of the study.
- Have received chemotherapy or radiation therapy within the past 5 years.
- Have clinical evidence of bacterial or fungal infection of the wound per visual/clinical assessment.
- Have a severe burn, immunodeficiency disorder, hematologic disorder, or metastatic malignancy.
- Have had documented osteomyelitis in the wound area within 6 months prior to screening.
- The Principal Investigator may declare any subject ineligible for a valid medical reason.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Active Comparator
Active Comparator
Other
Arm Label
HP011-101
HP828-101
Standard Care
Arm Description
Outcomes
Primary Outcome Measures
Change in Wound Bed Scores
Secondary Outcome Measures
Adverse Events
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01273428
Brief Title
HP011-101, HP828-101, and Standard Care for Pressure Ulcers
Official Title
Comparison of HP011-101, HP828-101, and Standard Care in the Management of Stage I-II Pressure Ulcers in Patients With Spinal Cord Injury
Study Type
Interventional
2. Study Status
Record Verification Date
January 2011
Overall Recruitment Status
Withdrawn
Why Stopped
The device test article is no longer available
Study Start Date
undefined (undefined)
Primary Completion Date
June 2011 (Anticipated)
Study Completion Date
November 2011 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
Healthpoint
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Testing a drug and a device for the treatment of pressure ulcers, compared with current treatments.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pressure Ulcers
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Care ProviderInvestigator
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
HP011-101
Arm Type
Active Comparator
Arm Title
HP828-101
Arm Type
Active Comparator
Arm Title
Standard Care
Arm Type
Other
Intervention Type
Drug
Intervention Name(s)
HP011-101
Intervention Type
Device
Intervention Name(s)
HP-828-101
Intervention Type
Other
Intervention Name(s)
Standard Care
Primary Outcome Measure Information:
Title
Change in Wound Bed Scores
Time Frame
22 days
Secondary Outcome Measure Information:
Title
Adverse Events
Time Frame
22 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subjects must meet all of the following criteria to be eligible for the study:
Provide informed consent, or informed assent if less than 18 years of age.
Age 12 years or older, of either sex, and of any race or skin type, provided that their skin color, in the opinion of the Investigator, will not interfere with the study assessments.
Have a pressure ulcer ≥ 5 cm² and ≤ 100 cm² in area (measured as greatest length x perpendicular width of the area of non-blanching erythema or denuded skin, whichever is greater), and will remain hospitalized for at least three weeks.
Are capable of maintaining an adequate nutritional status.
All female subjects must have a negative urinary pregnancy test.
Have, within 12 weeks prior to screening, clinical laboratory test results indicating:
Serum albumin ≥ 3.0 g/dL (30 g/L)
Alkaline phosphatase, ALT, AST, BUN and serum creatinine levels < 3x upper limit of the Healthpoint normal range (refer to Section 18.1.2)
HbA1C ≤ 12%
Hemoglobin ≥ 10 g/dL
The most recently obtained values must be evaluated against these criteria. If these values are not available from a blood sample within 12 weeks of screening, blood must be drawn at screening and these laboratory values determined.
For ulcers that will require surgical debridement prior to enrollment, the wound must be expected to remain a Stage I or Stage II partial thickness wound after debridement.
Exclusion Criteria:
Subjects meeting any of the following criteria are not eligible to enter the study:
Have a known hypersensitivity to any of the test articles or their components.
Have received therapy with another investigational agent within thirty (30) days of screening.
Are pregnant or nursing.
Are currently being treated with systemic antibiotics.
Have received systemic treatment with glucocorticoids for > 10 consecutive days within 1 month prior to the start of the study.
Have received chemotherapy or radiation therapy within the past 5 years.
Have clinical evidence of bacterial or fungal infection of the wound per visual/clinical assessment.
Have a severe burn, immunodeficiency disorder, hematologic disorder, or metastatic malignancy.
Have had documented osteomyelitis in the wound area within 6 months prior to screening.
The Principal Investigator may declare any subject ineligible for a valid medical reason.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Herbert B Slade, MD
Organizational Affiliation
Healthpoint, Ltd
Official's Role
Study Chair
12. IPD Sharing Statement
Learn more about this trial
HP011-101, HP828-101, and Standard Care for Pressure Ulcers
We'll reach out to this number within 24 hrs